https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45588 Wed 02 Nov 2022 10:40:43 AEDT ]]> [Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47980 Tue 21 Mar 2023 16:56:35 AEDT ]]> Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54742 Mon 11 Mar 2024 14:26:03 AEDT ]]>